Protocol Ledger

NCT06764238 · Phase II/III · RECRUITING

Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol

Interventional Phase II/III clinical trial protocol NCT06764238 sponsored by Institute of Hematology & Blood Diseases Hospital, China in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-01-03 Enrollment: 1,800 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06764238
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)1,800 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06764238
Protocol FieldVerified Registry Value
NCT IdentifierNCT06764238
Consolidated Lead SponsorInstitute of Hematology & Blood Diseases Hospital, China
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II/III
Overall Recruitment StatusRECRUITING
Registered Enrollment1,800 participants (ESTIMATED)
Registered Start Date2025-01-03
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI